KOSDAQBiotech & Pharma456160

G2gbio

₩43,700▲ 0.46%2026-10-02 close

Market Cap

₩725B

Turnover

₩12B

Volume

270,000 shares

Shares out.

16.6M

PER

—

PBR

—

EPS

-₩1,195

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Big Pharma Deals Expand, Profitability Still Ahead

G2GBio has signed a series of deals with partners including Boehringer Ingelheim and Samsung Bioepis around its InnoLAMP long-acting injectable platform, but revenue remains minimal and quarterly losses persist.

1
In March 2026, the company signed an exclusive license-out agreement with Samsung Bioepis and Epis NexLab covering two candidates including a semaglutide-based formulation.
2
2025 consolidated revenue was about KRW 423 million, still minimal, while operating loss stayed around KRW 12.2 billion, similar to the prior year.
3
In Q1-Q2 2026, net losses attributable to owners widened to roughly KRW 5.5-5.7 billion per quarter, exceeding operating losses, pointing to growing non-operating impacts.
4
Following its 2025 listing, total equity turned from negative to positive, improving the balance sheet structure.
5
Following the Samsung Bioepis deal announcement, the share price fell sharply, highlighting a gap between deal terms and market expectations.

Business structure

Founded in 2017, G2GBio is a developer specializing in long-acting injectable (LAI) drugs and is a pharmaceutical manufacturer listed on KOSDAQ on August 14, 2025. Its core technology is InnoLAMP, a proprietary platform that mass-produces uniformly sized microspheres using a membrane emulsification method.

The company has concentrated its pipeline on chronic and psychiatric conditions with low medication adherence, including dementia, obesity, and schizophrenia.

Its lead candidate, dementia treatment GB-5001, completed Phase 1 as what the company describes as the world's first one-month sustained-release formulation and has been licensed to two domestic pharmaceutical companies.

Global partnerships have also expanded: the company signed a formulation development agreement with Boehringer Ingelheim for long-acting injectable versions of peptide candidates focused on cardio-renal-metabolic disease, and in 2023 entered a master service agreement (MSA) with a US-based global pharmaceutical company covering microsphere sustained-release technology.

In March 2026, it signed a three-party agreement with Samsung Bioepis and Epis NexLab for exclusive license-out of two new drug candidates including a semaglutide-based obesity treatment, while retaining manufacturing and supply rights for the developed substances.

Globally, only around ten sustained-release injectable drugs have received FDA approval, reflecting high technical barriers, and domestically the company competes with Inventage Lab, which holds similar microsphere-based technology and has filed a patent invalidation trial against G2GBio.

Earnings trend

Quarterly revenue · Operating profit

₩200M-₩2.7B25Q2₩58,461,532-₩3.6B25Q3₩200M-₩3B25Q4₩400M-₩3.3B26Q1₩1.6B-₩2.7B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩700M-₩13.1B2023₩800M-₩10.8B2024₩400M-₩12.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩200M	-₩2.7B	−1789.3%
2025Q3	₩58,461,532	-₩3.6B	−6098.1%
2025Q4	₩200M	-₩3B	−1485.0%
2026Q1	₩400M	-₩3.3B	−944.6%
2026Q2	₩1.6B	-₩2.7B	−168.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2023	₩700M	-₩13.1B	-₩10.5B	−1776.7%	—	−182.4%
2024	₩800M	-₩10.8B	-₩83.3B	−1399.8%	—	−121.2%
2025	₩400M	-₩12.2B	-₩12.1B	−2884.2%	−20.7%	16.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Consolidated revenue in 2025 was about KRW 423 million, actually down from roughly KRW 769 million in 2024 and KRW 740 million in 2023.

Operating loss was about KRW 12.2 billion in 2025, compared with roughly KRW 10.8 billion in 2024 and KRW 13.1 billion in 2023, showing losses persisting in the tens of billions of won range each year without a clear trend change.

Net loss attributable to owners narrowed sharply to about KRW 12.1 billion in 2025 from roughly KRW 83.3 billion in 2024, which appears to reflect large one-time fair-value valuation losses related to pre-IPO redeemable convertible preferred shares and convertible bonds in 2024.

Indeed, total equity swung from about negative KRW 119.5 billion in 2024 to positive KRW 58.3 billion in 2025, and the debt ratio normalized from -121.2% in 2024 and -182.4% in 2023 to 16.1% in 2025, showing a clear improvement in capital structure following the listing.

On a quarterly basis from Q2 2025 through Q2 2026, revenue moved roughly from KRW 0.15 billion to 0.06 billion, 0.20 billion, 0.35 billion, and then jumped to about KRW 1.6 billion in Q2 2026.

However, operating losses stayed in a roughly KRW 2.7-3.6 billion range each quarter without material improvement, while net losses attributable to owners widened to about KRW 5.5 billion in Q1 2026 and KRW 5.7 billion in Q2 2026, exceeding operating losses and pointing to a growing impact from non-operating items.

Operating cash flow also showed a larger outflow of about negative KRW 13.9 billion in 2025 versus roughly negative KRW 8.0 billion in 2024 and negative KRW 11.0 billion in 2023, reflecting continued R&D investment burden.

Given the size and volatility of revenue to date, it appears to be driven not by commercial product sales but by irregular recognition of license contract fees and milestones.

Industry analysis

The long-acting injectable (LAI) market has steadily expanded as an alternative to oral medication in chronic and psychiatric disease areas with low adherence.

In the schizophrenia treatment market, Janssen's Invega grew from about $430 million in 2009 to about $3.1 billion in 2018, with the oral drug share falling from 92% to 7% over the same period while the one-month injectable share rose from 8% to 78%, and combined sustained-release injectable share (including three-month formulations) reaching 93%.

In the obesity treatment market, high-dose dual and triple agonists such as cagrisema, tirzepatide, and retatrutide face technical challenges developing once-monthly formulations due to their high dosing requirements, and G2GBio has disclosed one-month pharmacokinetic (PK) data demonstrating subcutaneous (SC) formulation feasibility through its high-loading drug technology.

The sustained-release injectable field has high technical barriers, with only about ten FDA-approved products globally, creating a landscape where a small number of platform companies are selected as partners by global big pharma.

Domestically, the company competes with Inventage Lab, which holds similar microsphere-based technology, and legal disputes over patents have also arisen.

Amid this competitive landscape, G2GBio is at a stage of having its platform's commercial value validated through agreements with major partners including Boehringer Ingelheim and Samsung Bioepis/Epis NexLab.

Outlook

In the first half of 2026, G2GBio continued its partnership expansion by attending a series of global events including the American Diabetes Association (ADA) meeting, CPHI China, and BIO USA.

At BIO USA in June, the company held individual meetings with more than 40 parties, discussing new candidate substances with existing co-development partners as well as licensing and CDMO collaboration with companies from the US, Europe, Japan, South America, Canada, and China.

Earlier in March, the company signed an exclusive license-out agreement with Samsung Bioepis and Epis NexLab covering two candidates including a semaglutide-based obesity treatment, and secured a right of first negotiation on up to three additional candidates, including new drug substances.

CEO Lee Hee-yong stated that the deal was significant because "it secures manufacturing rights that will allow the company to supply products to the global market in conjunction with the second GMP facility it plans to build." The company is also simultaneously advancing peptide formulation development for cardio-renal-metabolic disease with Boehringer Ingelheim, reflecting multiple global partnerships proceeding in parallel.

However, most disclosed contracts to date are conditional structures in which revenue is realized only upon successful clinical trials and regulatory approval, meaning additional clinical progress and regulatory procedures are needed before these translate into commercial sales.

Valuation

PER

—

PBR

—

ROE

-23.7%

EPS

-₩1,195

BPS

—

Dividend per share

₩0

G2GBio has yet to generate clear commercial revenue and remains in a loss-making stage, which limits conventional earnings-based valuation comparisons.

The share price appears to trade at a premium to net asset value, which can be interpreted as reflecting market expectations for future clinical progress and global partnership outcomes rather than current results. As no dividend is paid, dividend-related metrics carry limited meaning at present.

The 2025 listing-driven shift of total equity from negative to positive is a relevant reference point for the balance sheet, though it does not by itself signal a recovery in profitability.

Notably, the sharp share price decline following the March 2026 Samsung Bioepis deal announcement illustrates that the market can react more sensitively to a partner's name recognition and detailed contract terms, such as clawback obligations on upfront payments, than to the headline scale of a deal.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Multiple partnerships with global pharma

Multiple large partnerships are proceeding simultaneously, including a formulation development agreement with Boehringer Ingelheim for cardio-renal-metabolic peptides, a 2023 master service agreement with a US global pharmaceutical company, and the March 2026 exclusive license-out deal with Samsung Bioepis and Epis NexLab.

The Samsung Bioepis agreement is reported to include upfront payment, milestones, and royalties in addition to manufacturing and supply rights.

Even accounting for the fact that these contracts are contingent on clinical success, having the platform technology validated by multiple global companies can be viewed as a positive signal.

Differentiated high-dose drug loading technology

High-dose dual and triple agonists such as cagrisema, tirzepatide, and retatrutide face technical difficulty developing once-monthly formulations due to their dosing requirements, and G2GBio has presented one-month PK data using its high-loading InnoLAMP technology, suggesting the feasibility of a subcutaneous (SC) formulation.

This can be seen as evidence of potential to resolve a technical challenge relative to competing sustained-release injectable technologies. However, this is preclinical or early-stage data, and further validation is needed before commercialization.

Improved balance sheet following listing

Total equity swung from about negative KRW 119.5 billion in 2024 to positive KRW 58.3 billion in 2025, and the debt ratio normalized from -121.2% to 16.1%. This appears to reflect the resolution of pre-IPO burdens related to redeemable convertible preferred shares and convertible bonds following the listing. The improved balance sheet is a positive factor in terms of capacity to fund continued R&D.

Bear factors

Absence of commercial revenue and persistent losses

2025 revenue of about KRW 423 million was actually lower than in 2024, and operating losses have continued in the tens-of-billions-of-won range every year. In Q1-Q2 2026, net losses widened further than operating losses, indicating a growing burden from non-operating factors.

With no clear timeline for a shift to commercial revenue, the fact that loss levels have not narrowed is a headwind.

Market disappointment over the Samsung Bioepis deal

Following the March 2026 announcement of the deal with Samsung Bioepis and Epis NexLab, disappointment that this was not a direct deal with the global big pharma the market had anticipated, combined with clawback provisions on the upfront payment and milestones, contributed to a 22.9% share price decline over the three trading days after the announcement.

Shinyoung Securities commented that attention should focus on the substance of the deal rather than the partner's name recognition. The market reaction shows heightened sensitivity to partner choice and detailed terms, separate from the merits of the deal itself.

Patent dispute with a competitor

Domestic competitor Inventage Lab has filed a patent invalidation trial against G2GBio. The company argues this is evidence that its patent is effectively functioning, but legal uncertainty remains until the trial outcome is determined.

Patent-related disputes are a factor that could affect the exclusivity of the pipeline and future licensing negotiating power.

Risk factors

Contingent contract structure

Key license agreements, including the Samsung Bioepis deal, are structured so that revenue is recognized contingent on the success of clinical trials, product approvals, and regulatory clearance.

Disclosures state that contracts may be terminated midway due to co-research progress issues, clinical failure, or failure to obtain regulatory approval. This means contract signing itself does not directly translate into confirmed revenue.

Clawback obligations on upfront and milestone payments

Disclosures for the Samsung Bioepis deal state that a portion of the upfront payment and staged milestones could be subject to repayment under certain conditions within a set period.

Since upfront payments in typical technology licensing deals are often non-refundable, such provisions add uncertainty to future cash flow. If the contract is terminated early, part of the revenue already recognized could potentially be clawed back.

Patent and intellectual property disputes

A patent invalidation trial filed by competitor Inventage Lab is ongoing, a matter that could affect the exclusivity of intellectual property related to the company's core pipeline. Depending on the outcome, there could be ripple effects on licensing negotiating power and relationships with existing contract partners. The final outcome and timing of the legal dispute remain uncertain at this stage.

What to watch next

Mid-November 2026 (around the statutory Q3 report filing deadline)
Check the Q3 2026 earnings disclosure to see whether revenue recognition (license milestones) and the trend in operating and net losses show improvement compared to prior quarters.
Upon updates on the Samsung Bioepis/Epis NexLab joint research
Monitor whether an investigational new drug (IND) application is filed for the semaglutide-based candidate and whether progress is made on the additional three candidates subject to the right of first negotiation.
Upon the ruling on the patent invalidation trial filed by Inventage Lab
Assess how the trial ruling affects the company's core patents and pipeline exclusivity.
Upon disclosures related to the second GMP production facility
When concrete disclosures on construction start, investment size, and operational timeline emerge, assess the feasibility of the capacity expansion plan.

Overall view

G2GBio is at a stage of having its technology validated through agreements with major partners such as Boehringer Ingelheim and Samsung Bioepis/Epis NexLab based on its InnoLAMP platform, but most of these contracts are contingent structures where revenue is realized only upon clinical success. 2025 revenue was only in the hundreds of millions of won range, operating losses have continued at tens of billions of won annually, and in the first half of 2026 net losses widened even more than operating losses.

While the balance sheet improved following the listing, with total equity turning from negative to positive, this does not by itself signal a recovery in profitability.

The sharp share price decline following the Samsung Bioepis deal announcement shows that the market reacts sensitively to partner name recognition and detailed contract terms.

Key items to watch going forward include the clinical and regulatory execution of contingent contracts, exercise of the right of first negotiation on additional candidates, the outcome of the patent dispute, and progress on building the second GMP facility.

Continuously verifying whether these contingent elements materialize appears important before forming any investment judgment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.